Oral Cancer Prevention

Oral and Maxillofacial Surgery Clinics of North America

Volumn 18, Issue 4, 2006, Pages 493-511

  Kuriakose, M Abraham ^a,b   Sharan, Rajeev ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ALPHA2A INTERFERON; BETA CAROTENE; BOWMANN BIRK INHIBITOR; CELECOXIB; CETUXIMAB; CURCUMIN; CYCLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FENRETINIDE; GARLIC EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOTRETINOIN; KETOROLAC; PLACEBO; PROTEIN P16; PROTEIN P53; PROTEINASE INHIBITOR; RAS PROTEIN; RETINOID; RETINOL; RETINOL PALMITATE; SELENIUM; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONJUNCTIVITIS; DERMATITIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; EARLY DIAGNOSIS; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LEUKOPLAKIA; MALIGNANT TRANSFORMATION; MOUTH CANCER; NONHUMAN; PREVALENCE; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 33751012436     PISSN: 10423699     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coms.2006.06.003     Document Type: Review

References (131)

1. Mignogna M.D., Fedele S., Lo Russo L., et al. Oral and pharyngeal cancer: lack of prevention and early detection by health care providers. Eur J Cancer Prev 10 (2001) 381-383
2. Lippman S.M., and Hong W.K. Molecular markers of the risk of oral cancer. N Engl J Med 344 (2001) 1323-1326
3. Mao L., Hong W.K., and Papadimitrakopoulou V.A. Focus on head and neck cancer. Cancer Cell 5 (2004) 311-316
4. Abbruzzese J.L., and Lippman S.M. The convergence of cancer prevention and therapy in early phase clinical drug development. Cancer Cell 6 (2004) 321-326
5. Brennan J.A., Boylo J.O., Koch W.M., et al. Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med 332 (1995) 712-717
6. Wu X., Lippman S.M., Lee J.J., et al. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res 62 (2002) 2813-2818
7. Shin D.M., Charuruks N., Lippman S.M., et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 10 (2001) 603-609
8. Slaughter D.P., Southwick H.W., and Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6 (1953) 963-968
9. Braakhuis B.J., Tabor M.P., Kummer J.A., et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63 (2003) 1727-1730
10. Jang S.J., Chiba I., Hirai A., et al. Multiple oral squamous epithelial lesions: are they genetically related?. Oncogene 20 (2001) 2235-2242
11. Weisberger D. Precancerous lesions. J Am Dent Assoc 54 (1957) 507-508
12. Einhorn J., and Wersall J. Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa. Cancer 20 (1967) 2189-2193
13. Silverman S.J. Observations on the clinical characteristics and natural history of oral leukoplakia. J Am Dent Assoc 76 (1968) 772-777
14. Silverman S.J., Bhargava K., Mani N.J., et al. Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers in Gujarat, India. Cancer 38 (1976) 1790-1795
15. Silverman S.J., Gorsky M., and Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 53 (1984) 563-568
16. Neville B.W., and Day T.A. Oral cancer and precancerous lesions. CA Cancer J Clin 52 (2002) 195-215
17. Roed-Petersen B. Cancer development in oral leukoplakia: follow-up of 331 patients. J Dent Res 50 (1971) 711
18. Kulasegaram R., Downer M.C., Jullien J.A., et al. Case-control study of oral dysplasia and risk habits among patients of a dental hospital. Eur J Cancer 31 (1995) 227-231
19. Wynder E.L., Bross J.J., and Feldman R.M. A study of the etiologic factors in cancer of the mouth. Cancer 10 (1957) 1300-1323
20. Rothamn K.J., and Keller A.Z. The effect of joint exposure to alcohol and tobacco on the risk of cancer of the mouth and pharynx. J Chronic Dis 25 (1972) 711-716
21. Graham S., Dayal H., and Rohrer T. Dentition, diet, tobacco and alcohol in the epidemiology of oral cancer. J Natl Cancer Inst 59 (1977) 1611-1618
22. Brugere J., Guenel P., Leclerc A., et al. Differential effects of tobacco and alcohol in cancer of the larynx, pharynx and mouth. Cancer 57 (1986) 391-395
23. Mashberg A., Boffetta P., Winkelman R., et al. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among US veterans. Cancer 72 (1993) 1369-1375
24. Shiu M.N., Chen T.H.H., Chang S.H., et al. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br J Cancer 82 (2000) 1871-1874
25. Martin G.C., Brown J.P., Eifler C.W., et al. Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J Am Dent Assoc 130 7 (1999) 945-954
26. Schinke S.P., Gilchrist L.D., Schilling II R.F., et al. Smoking and smokeless tobacco use among adolescents: trends and intervention results. Public Health Rep 101 4 (1986) 373-378
27. Sankaranarayanan R., Nair M.K., Mathew B., et al. Recent results of oral cancer research in Kerala, India. Head Neck 14 (1992) 107-112
28. Sussman S., Dent C.W., Stacy A.W., et al. Project towards no tobacco use: 1-year behaviour outcomes. Am J Public Health 83 (1993) 1245-1250
29. Elder J.P., Wildey M., de Moor C., et al. The long term prevention of tobacco use among junior high school students: classroom and telephone interventions. Am J Public Health 83 9 (1993) 1239-1244
30. Stevens M.M., Freeman Jr. D.H., Mott L.A., et al. Smokeless tobacco use among children: the New Hampshire study. Am J Prev Med 9 (1993) 160-167
31. Shiu M.-N., and Chen T.H.-H. Impact of betel quid, tobacco and alcohol on three-stage disease natural history of oral leukoplakia and cancer: implication for prevention of oral cancer. Eur J Cancer Prev 13 (2004) 39-45
32. American Cancer Society. Update January 1992: the American Cancer Society guidelines for the cancer -related checkup. CA Cancer J Clin 42 (1992) 44-45
33. British Dental Association. Oral cancer: guidelines for early detection. Occasional paper no. 5; London: British Dental Association; 1998.
34. Workgroup of the UICC Epidemiology and Prevention Programme. Progress report from the workgroup on the success of prevention and detection programmes (2001), International Union Against Cancer, Geneva (Switzerland)
35. Burzynski N., Firriolo F.J., Butters J.M., et al. Evaluation of oral cancer screening. J Cancer Educ 12 (1997) 95-99
36. Mignogna M.D., Fedele S., Lo Russo L., et al. Costs and effectiveness in the care of patients with oral and pharyngeal cancer: analysis of a paradox. Eur J Cancer Prev 11 (2002) 205-208
37. Allison P., Locker D., and Feine J.S. The role of diagnostic delays in the prognosis of oral cancer: a review of the literature. Oral Oncol 34 (1998) 161-170
38. Mashberg A. Diagnosis of early oral and oropharyngeal squamous carcinoma: obstacles and their amelioration. Oral Oncol 36 (2000) 253-255
39. Mignogna M.D., Fedele S., and Lo Russo L. The world cancer report and the burden of oral cancer. Eur J Cancer Prev 13 (2004) 139-142
40. th Asia Pacific Cancer Conference. Madras, India, December 15, 1999.
41. Warnakulasuriya K.A.A.S., Ekanayake A.N.I., Sivayoham S., et al. Utilisation of primary care workers for early detection of oral cancer and precancer cases in Sri Lanka. Bull World Health Organ 62 (1984) 243-250
42. Warnakulasuriya K.A.A.S., and Nanayakkara B.G. Reproducibility of an oral cancer and precancer detection program using a primary health care model in Sri Lanka. Cancer Detect Prev 15 (1991) 331-334
43. Mehta F.S., Gupta P.C., Bhonsle R.B., et al. Detection of oral cancer using basic health workers in an area of high oral cancer incidence in India. Cancer Detect Prev 9 (1986) 219-225
44. Mathew B., Sankaranarayanan R., Sunilkumar K.B., et al. Reproducibility and validity of oral visual inspection by trained health workers in the detection of oral precancer and cancer. Br J Cancer 76 (1997) 390-394
45. Mathew B., Wesley R., Dutt S.C., et al. Cancer screening by local volunteers. World Health Forum 17 (1996) 377-378
46. Mashberg A., and Barsa P. Screening for oral and oropharyngeal squamous cell carcinomas. CA Cancer J Clin 34 (1984) 262-268
47. Fernandez Garrote L., Sankaranarayanan R., Lence Anta J.J., et al. An evaluation of the oral cancer control programme in Cuba. Epidemiology 6 (1995) 428-431
48. Mathew B., Sankaranarayanan R., Wesley R., et al. Evaluation of mouth self-examination in the control of oral cancer. Br J Cancer 71 (1995) 397-399
49. Moles D.R., Downer M.C., Speight P.M., et al. Meta-analysis of measures of performance reported in oral cancer and precancer screening studies. Br Dent J 192 6 (2002) 340-344
50. Sankaranarayanan R., Ramadas K., Thomas G., et al. for the Trivandrum Oral Cancer Screening Study Group. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 365 (2005) 1927-1933
51. Allison P., Franco E., Black M., et al. The role of professional diagnostic delays in the prognosis of upper aerodigestive tract carcinoma. Oral Oncol 34 2 (1998) 147-153
52. Allison P., Franco E., and Feine J. Predictors of professional diagnostic delays for upper aerodigestive tract carcinoma. Oral Oncol 34 2 (1998) 127-132
53. Kerdpon D., and Sriplung H. Factors related to advanced stage oral squamous cell carcinoma in southern Thailand. Oral Oncol 37 3 (2001) 216-221
54. Leao J.C., Goes P., Sobrinho C.B., et al. Knowledge and clinical expertise regarding oral cancer among Brazilian dentists. Int J Oral Maxillofac Surg 34 (2005) 436-439
55. Clovis J.B., Horowitz A.M., and Poel D.H. Oral and pharyngeal cancer: knowledge and opinions of dentists in British Columbia and Nova Scotia. J Can Dent Assoc 68 7 (2002) 415-420
56. Macpherson L.M., McCann M.F., Gibson J., et al. The role of primary healthcare professionals in oral cancer prevention and detection. Br Dent J 195 5 (2003) 277-281
57. Smith R.A., Cokkinides V., and Eyre H.J. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 53 (2003) 27-43
58. Nicotera G., Gnisci F., Bianco A., et al. Dental hygienists and oral cancer prevention: knowledge, attitudes and behaviors in Italy. Oral Oncol 40 (2004) 638-644
59. Lippman S.M., Benner S.E., and Hong W.K. Cancer chemoprevention. J Clin Oncol 12 (1994) 851-873
60. Hong W.K., et al. 13-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315 (1986) 1301
61. Stich H.F., Homby A.P., Mathew B., et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 40 (1988) 93-101
62. Lippman S.M., Batsakis J.G., Toth B.B., et al. Comparison of low-dose isotretinoin with beta-carotene to prevent oral carcinogenesis. N Engl J Med 328 (1993) 15
63. Han J., Jiao L., Lu Y., et al. Evaluation of N-4-(hydroxycarbophanyl) retinamide as a cancer prevention agent and as a cancer chemotherepeutic agent. In Vivo 4 (1990) 153-160
64. Chiesa F., Tradati N., Marazza M., et al. Prevention of local relapses and new localisatons of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR): preliminary results. Eur J Cancer B Oral Oncol 28B (1992) 97-102
65. Hong W.K., Lippman S.M., Itri L.M., et al. Prevention of second primary tumors with 13cRA in squamous-cell carcinoma of the head and neck. N Engl J Med 323 (1990) 795
66. Benner S.E., Winn R.J., Lippman S.M., et al. Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemoprevention study. J Natl Cancer Inst 85 (1993) 44-47
67. Khuri F.R., Kim E.S., Lee J.J., et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarker Prev 10 8 (2001) 823-829
68. Khuri F.R., Lee J.J., Lippman S.M., et al. Isotretinoin effects on head and neck cancer recurrence and second primary tumors. [abstract 359]. Proc Am Soc Clin Oncol 22 (2003) 90
69. van Zandwijk N., Dalesio O., Pastorino U., et al. EUROSCAN: a randomized trial of vitamin A and N-Acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 92 (2000) 977-986
70. Papadimitrakopoulou V.A., Clayman G.L., Shin D.M., et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 125 10 (1999) 1083-1089
71. Shin D.M., Khuri F.R., Murphy B., et al. combined interferon-alpha, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19 (2001) 3010-3017
72. Shin D.M., Richards T.J., and Seixas-Silva J.A. Phase II trial of bioadjuvant therapy with interferon-alpha2a, 13-cis-retinoic acid, and alpha-tocopherol for locally advanced squamous cell carcinoma of the head and neck: long term follow up. Proc Am Soc Clin Oncol 2003 (1995) 22
73. Lippman S., Shin D., Lee J., et al. p53 and retinoid chemoprevention of oral carcinogenesis. Clin Cancer Res 55 (1995) 16-19
74. Toma S., Bonelli L., Sartoris A., et al. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 11 6 (2004) 1297-1305
75. Toma S., Coialbu T., Collecchi P., et al. Biological aspects and perspectives applicable to the chemoprevention of the cancer of the upper respiratory-digestive tract. Acta Otorhinolaryngol Ital 10 Suppl 27 (1990) 41-54
76. Armstrong W.B., Wan X.S., Kennedy A.R., et al. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope 113 10 (2003) 1687-1702
77. Messadi D.V., Billings P., Schklar G., et al. Inhibition of oral carcinogenesis by a protease inhibitor. J Natl Cancer Inst 76 (1986) 447-452
78. Armstrong W.B., Kennedy A.R., Wan X.S., et al. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 9 (2000) 43-47
79. Armstrong W.B., Kennedy A.R., Wan X.S., et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6 (2000) 4684-4691
80. Sharma O.P. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 25 (1976) 1811-1812
81. Toda S., Arichi H., Tanizawa H., et al. Natural antioxidant III: antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharm Bull (Tokyo) 33 (1985) 1725-1728
82. Ruby A.J., Babu K.D., Rajasekharan K.N., et al. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94 1 (1995) 79-83
83. In: Tonnesen H.H.C., Lee C.Y., and Haung M.T. (Eds). Phenolic compounds in food and their effect on health: analysis, occurrence and chemistry (1992), ACS Symposium Series No. 506 143-153
84. Srimal R.C. Pharmacology of diferuloylmethane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25 (1973) 447-452
85. Han S.-S., Chung S.-T., Robertson D.A., et al. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, C-myc, Bcl-XL, NF-B, and p53. Clin Immunol 93 2 (1999) 152-161
86. Kawamori T., Steele V.E., Kelloff G.J., et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59 (1999) 597-601
87. Arbiser J.L., Klauber N., Rohan R., et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4 6 (1998) 376-383
88. Rao C.V., Simi B., and Reddy B. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55 (1995) 259-266
89. Pereira M.A., Grubbs C.J., Barnes L.H., et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 17 6 (1996) 1305-1311
90. La Vecchia C., and Tavani A. Fruits and vegetables and human cancer. Eur J Cancer Prev 7 (1998) 3-8
91. Heber D., and Lu Q.-Y. Overview of mechanisms of action of lycopene. Exp Biol Med 227 (2002) 920-923
92. Kik C., Kahane R., and Gebhardt R. Garlic and health. Nutr Metab Cardiovasc Dis 11 (2001) 57-65
93. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 91 (1999) 317-331
94. Thomson M., and Ali M. Garlic (Allium sativum): a review of its potential use as an anti-cancer agent. Curr Cancer Drug Targets 3 (2003) 67-81
95. Breinholt V., Lauridsen S.T., Daneshvar B., et al. Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. Cancer Lett 154 (2000) 201-210
96. Gradelet S., Astorg P., Leclerc J., et al. Effects of canthaxanthin, astaxanthin, lycopene and lutein on liver xenobioticmetabolising enzymes in the rat. Xenobiotica 26 (1996) 49-63
97. Wu C.C., Sheen L.Y., Chen H.W., et al. Differential effects of garlic oil and its three major organosulfur components in the hepatic detoxification system in rats. J Agric Food Chem 50 (2002) 378-383
98. Bhuvaneswari V., Abraham S.K., and Nagini S. Combinatorial antigenotoxic and anticarcinogenic effects of tomato and garlic through modulation of xenobiotic-metabolizing enzymes during hamster buccal pouch carcinogenesis. Nutrition 21 (2005) 726-731
99. Saranath D., Chang S.E., Bhoite L.T., et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 63 (1991) 573-578
100. Kuo M.Y., Chang H.H., Hahn L.J., et al. Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinoma in Taiwan. J Oral Pathol Med 24 (1995) 255-260
101. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 1 (2000) 12-21
102. Rubin Grandis J., Melhem M.F., Gooding W.E., et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
103. Poon T.C.W., Chan A.T.C., and To K.F. Expression and prognostic significance of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma. [abstract 913]. Proc Am Soc Clin Oncol 20 (2001) 229
104. Santini J., Formento J.L., Francoual M., et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13 (1991) 132-139
105. Dassonville O., Formento J.L., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11 (1993) 1873-1878
106. Numico G., Colantonio I., Comino A., et al. EGFR and survival of patients with locally advanced head and neck cancer (HNC) and treated with alternating chemotherapy radiation (CT-RT): results of a retrospective analysis. [abstract 2018]. Proc Am Soc Clin Oncol 22 (2003) 501
107. Dannenberg A.J., Lippman S.M., Mann J.R., et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23 (2005) 254-266
108. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
109. Di Gennaro E., Barbarino M., Bruzzese F., et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195 (2003) 139-150
110. Huang S.M., Li J., and Harari P.M. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 1 (2002) 507-514
111. Matheny K.E., Barbieri C.E., Sniezek J.C., et al. Inhibition of epidermal growth factor receptor signaling decreases p53 expression in head and neck squamous carcinoma cells. Laryngoscope 113 (2003) 936-939
112. Kabrun N., and Enrietto P.J. The Rel family of proteins in oncogenesis and differentiation. Semin Cancer Biol 5 2 (1994) 103-112
113. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappa B. J Clin Invest 107 3 (2001) 241-246
114. Karin M., and Delhase M. The IkappaB kinase (IKK) and NF-kappa B: key elements of proinflammatory signaling. Semin Immunol 12 (2000) 85-98
115. Bharti A.C., and Aggarwal B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64 (2002) 883-888
116. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 49 (1999) 6853-6866
117. Yan Z., Subbaramaiah K., Camilli T., et al. Benzo(a)pyrene induces the transcription of cyclooxygenase-2 in vascular smooth cells: evidence for the involvement of extracellular signal-regulated kinase and NF-kappaB. J Biol Chem 275 7 (2000) 4949-4955
118. Rioux N., and Castonguay A. The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-kappaB. Carcinogenesis 21 9 (2000) 1745-1751
119. Li N., and Karin M. Ionising radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci U S A 95 22 (1998) 13012-13017
120. Loercher A., Lee T.L., Ricker J.L., et al. Nuclear factor-kB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64 (2004) 6511-6523
121. Harris C.C., and Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329 (1993) 1318-1327
122. Hartwell L.H., and Kastan M.B. Cell cycle control and cancer. Science 266 (1994) 1821-1828
123. Nees M., Homann N., Discher H., et al. Expression of mutated p53 occurs in tumor-distant epithelial head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 53 (1993) 4189-4196
124. Lee J.J., Hong W.K., Hittelman W.N., et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6 (2000) 1702-1710
125. Chung K.Y., Mukhopadhyay T., Kim J., et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Clin Cancer Res 53 (1993) 1676-1683
126. Zariwala M., Schmid S., Pfaltz M., et al. p53 gene mutations in oropharyngeal carcinomas: a comparison of solitary and multiple primary tumors and lymph-node metastases. Int J Cancer 56 (1994) 807-811
127. Gasparotto D., Maestro R., Brazan L., et al. Recurrences and second primary tumours in the head and neck region: differentiation by p53 mutation analysis. Ann Oncol 6 (1995) 933-939
128. Brennan J.A., Mao L., Hruban R.H., et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332 7 (1995) 429-435
129. Wang Z., Fuentes C.F., and Shapshay S.M. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 112 (2002) 839-843
130. Sood S., Shiff S.J., Yang C.S., et al. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncology 41 (2005) 562-567
131. Li N., Sood S., Wang S., et al. Overexpression of cyclooxygenase 2 and 5-lipoxygenase in hamster and human oral cancer and chemopreventive effects of celecoxib and zileuton. Clin Cancer Res 11 5 (2005) 2083-2088